MRI in right ventricular endomyocardial fibrosis

Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives

Tropical endomyocardial fibrosis (EMF) is a neglected disease of poverty that afflicts rural populations in tropical low-income countries, with some certain high-prevalence areas. Tropical EMF is characterized by the deposition of fibrous tissue in the endomyocardium, leading to restrictive physiology. Since the first descriptions in Uganda in 1948, high-frequency areas for EMF have included Africa, Asia, and South America. Although there is no clear consensus on a unified hypothesis, it seems likely that dietary, environmental, and infectious factors may combine in a susceptible individual to give rise to an inflammatory process leading to endomyocardial damage and scar formation. The natural history of EMF includes an active phase with recurrent flare-ups of inflammation evolving to a chronic phase leading to restrictive heart failure. In the chronic phase, biventricular involvement is the most common presentation, followed by isolated right-sided heart disease. Marked ascites out of proportion to peripheral edema usually develops as a typical feature of EMF. EMF carries a very poor prognosis. In addition to medical management of heart failure, early open heart surgery (endocardectomy and valve repair/replacement) appears to improve outcomes to some extent; however, surgery is technically challenging and not available in most endemic areas. Increased awareness among health workers and policy makers is the need of the hour for the unhindered development of efficient preventive and therapeutic strategies.

Recent advances in the epidemiology, diagnosis and treatment of endomyocardial fibrosis in Africa

Endomyocardial fibrosis (EMF) continues to be an important and disabling disease in many parts of Africa, although its prevalence has declined in some parts of the continent. Increased access to medical care in general and increased availability of echocardiography in some parts of the continent have led to recognition of the disease in areas in which the disease had not been previously reported, and this has given new insights into its natural history. However, the early manifestations of EMF continue to elude clinicians and researchers, and no progress has been made in defining its aetiology. Advances have, however, been made in establishing the epidemiology and improving clinical diagnosis and management, through modern medical therapy and improved surgical techniques. Research is still required to define clinical, biological and echocardiographic markers of early stages of EMF, so that advances in the knowledge of its pathogenesis and pathophysiology can be made. This will hopefully determine preventive measures and avoid the burden of this debilitating condition in this continent.

The Evolving Role of Cardiovascular Magnetic Resonance Imaging in Nonischemic Cardiomyopathy

Over the last several years, the role of cardiac magnetic resonance imaging in the diagnosis and management of heart failure has been rapidly expanding. The techniques unrivaled flexibility, accuracy in defining ventricular structure and function, and capacity to characterize tissue makes it particularly well suited for the study of the nonischemic cardiomyopathies. In this article, we provide an overview of the existing literature highlighting the diagnostic utility and prognostic power of cardiac magnetic resonance imaging in the nonischemic cardiomyopathies.

Imaging cardiac structure and pump function

This article describes magnetic resonance imaging approaches for assessing cardiac structure and myocardial pump function. The article is divided into cardiac structure and ventricular function. Throughout, representative images are included. There are numerous applications of magnetic resonance imaging for assessing cardiac structure and function, and magnetic resonance imaging compared favorably to other imaging modalities.